title: Experience With the Priority Review Voucher Program for Drug Development.
authors.affiliation: Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard Medical School, Boston, Massachusetts.
authors.forename: Aaron S
authors.initials: AS
authors.lastname: Kesselheim
authors.affiliation: Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard Medical School, Boston, Massachusetts.
authors.forename: Lara R
authors.initials: LR
authors.lastname: Maggs
authors.affiliation: Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard Medical School, Boston, Massachusetts.
authors.forename: Ameet
authors.initials: A
authors.lastname: Sarpatwari
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics; D000962:Antimalarials / Q000191:economics; D000970:Antineoplastic Agents / Q000191:economics; D000981:Antiprotozoal Agents / Q000191:economics; D000995:Antitubercular Agents / Q000191:economics; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins / Q000191:economics; D019826:Cholic Acid / Q000191:economics; D002811:Chondroitinsulfatases / Q000191:economics; D064687:Diarylquinolines / Q000191:economics; D017277:Drug Approval / Q000191:economics* / Q000331:legislation & jurisprudence / Q000379:methods; D004338:Drug Combinations; D004345:Drug Industry / Q000191:economics* / Q000331:legislation & jurisprudence; D004983:Ethanolamines / Q000191:economics; D005449:Fluorenes / Q000191:economics; D006801:Humans; D058069:Neglected Diseases / Q000188:drug therapy*; D010767:Phosphorylcholine / Q000031:analogs & derivatives / Q000191:economics; D016730:Program Development / Q000191:economics*; D035583:Rare Diseases / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000911:Antibodies, Monoclonal; D000962:Antimalarials; D000970:Antineoplastic Agents; D000981:Antiprotozoal Agents; D000995:Antitubercular Agents; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins; D064687:Diarylquinolines; D004338:Drug Combinations; D004983:Ethanolamines; D005449:Fluorenes; D010767:Phosphorylcholine; C039128:miltefosine; C493870:bedaquiline; C112746:dinutuximab; D002811:Chondroitinsulfatases; C102295:GALNS protein, human; D019826:Cholic Acid